+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Peripheral Neuropathy - Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 4968510
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 167 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Aptinyx
  • Glenmark Pharmaceuticals
  • Grünenthal GmbH
  • Helixmith
  • Novaremed Ltd.
  • Regenacy Pharmacuticals
  • MORE
‘Diabetic Peripheral Neuropathy - Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Diabetic Peripheral Neuropathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Diabetic Peripheral Neuropathy from 2017 to 2030 segmented by seven major markets.

Diabetic peripheral neuropathy (DPN) also known distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.

The signs and symptoms of DPN include numbness, tingling, poor balance, pain: burning, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others.

The clinical manifestations of DPN include painful diabetic neuropathy (pDPN) that is often accompanied by burning pain, aching, shooting, stabbing and paresthesia or allodynia often present in arms, hands, legs, and feet. DPN without painful symptoms is referred to as nonpainful diabetic neuropathy (non-pDPN). Due to the presence of pain, pDPN patients are expected to get diagnosed and expected to incur higher health care costs compared to the general population and non-pDPN.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Diabetic Peripheral Neuropathy - Disease Understanding and Treatment Algorithm

As per the American Diabetes Association, most common among diabetic neuropathies are chronic DPN, accounting for about 75% of the diabetic neuropathies. It is common prevalent complication in neurological damage of Type 1 and Type 2 diabetes, main risk factors contributing to DPN are smoking, obesity, hyperlipidemia, duration of diabetes, large total exposure to hyperglycemia, advanced age, elevated lipid levels, elevated blood pressure, kidney disease, cigarette smoking, overweight, increased height, and others.

The signs and symptoms of DPN include numbness, tingling, poor balance, pain: burning, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others.

Diabetic Peripheral Neuropathy Epidemiology

The Diabetic Peripheral Neuropathy epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

The publisher's estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017. Among 7MM, United States has the prevalent population of Diabetic Peripheral Neuropathy with about 12,522,483 cases in 2017. Among EU-5 countries, Germany has the highest prevalent cases with 3,904,730 cases, followed by Italy with 1,636,426 cases in 2017. However, Spain has the least number of diagnosed prevalent cases. All these cases are expected to increase by 2030.

Diabetic Peripheral Neuropathy Drug Chapters

This segment of the Diabetic Peripheral Neuropathy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The management of pain remains the key aspect of symptom treatment for DPN. The current medications fall into categories, such as antidepressants, anticonvulsants, topical agents and opioids. Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group.

Treatments currently approved by both FDA and EMA for pain associated with DPN include - pregabalin, duloxetine, and extended-release tapentadol and capsaicin 8% patch. However, no treatments have been approved for the prevention or reversal of DPN.

Given the increasing population with diabetic peripheral neuropathy and the impact on their quality of life, an overview of effective treatments is warranted. Thus, it is important to establish the pathogenesis of pDPN and identify a therapeutic target. As microvascular complication is one of the factors to develop pDPN, patients may need a treatment targeting the improvement of blood circulation.

Various pharmaceutical companies are developing therapies such as VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others which are expected to enter the market by 2030 as effective therapies.

Diabetic Peripheral Neuropathy Market Outlook

The Diabetic Peripheral Neuropathy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to the publisher, the market of Diabetic Peripheral Neuropathy in 7MM was found to be approximately USD 2,275.52 Million in 2017.

Diabetic Peripheral Neuropathy market size in the United States was maximum of the total market in 2017, followed by the EU5 and Japan respectively.

Diabetic Peripheral Neuropathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Various pharmaceutical companies are developing therapies such as VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others which are expected to enter the market by 2030 as effective therapies.

Diabetic Peripheral Neuropathy Report Insights
  • Patient Population of Diabetic Peripheral Neuropathy
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Diabetic Peripheral Neuropathy Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Diabetic Peripheral Neuropathy Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Diabetic Peripheral Neuropathy market
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Peripheral Neuropathy market
  • To understand the future market competition in the Diabetic Peripheral Neuropathy market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aptinyx
  • Glenmark Pharmaceuticals
  • Grünenthal GmbH
  • Helixmith
  • Novaremed Ltd.
  • Regenacy Pharmacuticals
  • MORE
1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy (DPN): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of DPN in 2017
3.2. Total Market Share (%) Distribution of DPN in 2030

4. Epidemiology and Market Methodology

5. Disease Background and Overview: Diabetic Peripheral Neuropathy (DPN)
5.1. Introduction
5.2. Classification of Diabetic Neuropathies
5.3. Signs and Symptoms
5.4. Risk Factors
5.5. Pathogenesis
5.6. Diagnosis
5.7. Recent developments in early diagnosis of DPN with POCDs
5.8. Differential Diagnosis

6. Epidemiology and Patient Population: Diabetic Peripheral Neuropathy (DPN)
6.1. Key Findings
6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy (DPN) in 7MM
6.3. United States
6.3.1. Assumptions and Rationale
6.3.2. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the United States
6.3.3. Gender-Specific Cases of Diabetic Peripheral Neuropathy in the United States
6.3.4. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the United States
6.4. EU5
6.4.1. Assumptions and Rationale
6.5. Germany
6.5.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Germany
6.5.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Germany
6.5.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Germany
6.6. France
6.6.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in France
6.6.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in France
6.6.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in France
6.7. Italy
6.7.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Italy
6.7.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Italy
6.7.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Italy
6.8. Spain
6.8.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Spain
6.8.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Spain
6.8.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Spain
6.9. United Kingdom (UK)
6.9.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the UK
6.9.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in the UK
6.9.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the UK
6.10. Japan
6.10.1. Assumptions and Rationale
6.10.2. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Japan
6.10.3. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Japan
6.10.4. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Japan

7. Treatment and Management of DPN
7.1. Guidelines for the management of DPN

8. Unmet need

9. Marketed Drugs
9.1. Key cross competition
9.2. Qutenza: Grünenthal
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Other developmental activities
9.2.4. Clinical Development
9.2.5. Safety and Efficacy
9.2.6. Product Profile
9.3. Tarlige: Daiichi Sankyo
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Other developmental activities
9.3.4. Clinical Development
9.3.5. Safety and Efficacy
9.3.6. Product Profile

10. Emerging drugs
10.1. Key cross competition
10.2. VM202: Helixmith
10.2.1. Drug Description
10.2.2. Other developmental activities
10.2.3. Clinical Development
10.2.4. Clinical trials information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. NYX-2925: Aptinyx
10.3.1. Drug Description
10.3.2. Other developmental activities
10.3.3. Clinical Development
10.3.4. Clinical trials information
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.4. WST-057: WinSanTor
10.4.1. Drug Description
10.4.2. Other developmental activities
10.4.3. Clinical Development
10.4.4. Clinical trials information
10.4.5. Product Profile
10.5. Ricolinostat: Regenacy Pharmaceuticals
10.5.1. Drug Description
10.5.2. Other developmental activities
10.5.3. Clinical Development
10.5.4. Clinical trials information
10.5.5. Safety and Efficacy
10.5.6. Product Profile
10.6. Cebranopadol: Grünenthal
10.6.1. Drug Description
10.6.2. Other developmental activities
10.6.3. Clinical Development
10.6.4. Clinical trials information
10.6.5. Safety and Efficacy
10.6.6. Product Profile
10.7. ISC 17536: Ichnos Science
10.7.1. Drug Description
10.7.2. Other developmental activities
10.7.3. Clinical Development
10.7.4. Clinical trials information
10.7.5. Safety and Efficacy
10.7.6. Product Profile
10.8. NRD135S.E1: Novaremed
10.8.1. Drug Description
10.8.2. Clinical Development
10.8.3. Clinical trials information
10.8.4. Safety and Efficacy
10.8.5. Product Profile
10.8.6. Other potential therapies
10.9. MEDI7352: AstraZeneca
10.9.1. Drug Description
10.9.2. Clinical Development
10.9.3. Clinical trials information
10.9.4. Product Profile
10.10. Trazodone/Gabapentin: Angelini
10.10.1. Drug Description
10.10.2. Clinical Development
10.10.3. Clinical trials information
10.10.4. Product Profile

11. Market Size: Diabetic Peripheral Neuropathy
11.1. Key Findings
11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM
11.3. Market Outlook: 7 MM
11.4. United States
11.4.1. Total Market size of Painful Diabetic Peripheral Neuropathy in the US
11.4.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the US
11.5. EU5
11.6. Germany
11.6.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Germany
11.6.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Germany
11.7. France
11.7.1. Total Market size of Painful Diabetic Peripheral Neuropathy in France
11.7.1.1. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in France
11.8. Italy
11.8.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Italy
11.8.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Italy
11.9. Spain
11.9.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Spain
11.9.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Spain
11.10. United Kingdom
11.10.1. Total Market size of Painful Diabetic Peripheral Neuropathy in the UK
11.10.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the UK
11.11. Japan
11.11.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Japan
11.11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Japan

12. Reimbursement policies
12.1. Access and Reimbursement Overview for Current and Future Therapies
12.2. Current Therapies
12.2.1. Capsaicin patch (Qutenza)
12.2.2. Mirogabalin besilate (Tarlige)
12.3. Future Therapies
12.3.1. Gene Therapy
12.3.2. Disease-modifying Therapy

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Case Report

18. A Case Report of DPN

19. Bibliography

20. Appendix

21. Report Methodology

22. Publisher Capabilities

23. Disclaimer

24. About the Publisher
Note: Product cover images may vary from those shown
3 of 3
  • Helixmith
  • Aptinyx
  • WinSanTor, Inc.
  • Regenacy Pharmacuticals
  • Novaremed Ltd.
  • Grünenthal GmbH
  • Glenmark Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll